Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in aneurysmal subarachnoid hemorrhage
NCT05727657Phase 1Withdrawn
- Sponsor
- University of Florida
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of satralizumab in aneurysmal subarachnoid hemorrhage (SAH), sponsored by University of Florida. Primary endpoints: Number of participants with elevation of liver transaminases at 21 days, Number of participants with neutropenia at 21 days and 3 more. Planned start Jun 2024; status: withdrawn.
02
Drugs
satralizumab
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT05727657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727657.